KEY FINDINGS
The North America DNA sequencing market growth is predicted to progress at a CAGR of 16.83% during the forecast period, 2021-2028. The prevalence of different types of cancer primarily drives the market growth.
MARKET INSIGHTS
The United States and Canada are evaluated for the North America DNA sequencing market growth analysis. In Canada, the market growth is steady, accredited to growing funds and research projects. TCAG (The Centre for Applied Genomics) offers genomics support and analyses to over 800 scientific investigators from non-government, academic, and government organizations and private-sector research labs globally. It has been a Canadian Science and Technology Platform since 2001. In February 2018, the Canada 150 Sequencing Initiative (CanSeq150) launch resulted in an increased number of research activities and investment from the government for sequencing of 150 genomes of various species.
Moreover, Genome Canada, Thermo Fisher Scientific, and Ontario Institute for Cancer Research (OICR) collaborated in September 2019 to develop next-generation sequencing assays and analysis software targeting breast, prostate, and pancreatic cancers. Further, the Canadian COVID Genomics Network (CanCOGeN) was launched in April 2020 by Genome Canada. Such developments promote market growth in Canada.
COMPETITIVE INSIGHTS
Some of the market’s key players include Pacific Biosciences of California Inc, Illumina Inc, Ubiquity Genomics Inc, Siemens Healthineers AG, Thermo Fisher Scientific Inc, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
'
TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. INCREASING NEED FOR DNA SEQUENCING IN ANIMALS & PLANT REPRODUCTION
3.1.2. TECHNOLOGICAL DEVELOPMENTS
3.1.3. GROWING RESEARCH AND DEVELOPMENT IN DNA SEQUENCING
3.1.4. PREVALENCE OF CANCER CASES
3.1.5. USAGE OF LIQUID BIOPSY APPLICATIONS
3.1.6. IMPLEMENTATION OF GENOME MAPPING PROGRAMS
3.2. KEY RESTRAINTS
3.2.1. ACCURACY AND STANDARDIZATION CONCERNS IN DIAGNOSTIC TESTING
3.2.2. LIMITATIONS IN BIOINFORMATICS
3.2.3. SOCIAL AND ETHICAL ISSUES
4. KEY ANALYTICS
4.1. IMPACT OF COVID-19 ON DNA SEQUENCING MARKET
4.2. KEY MARKET TRENDS
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTION
4.3.4. NEW ENTRY
4.3.5. INDUSTRY RIVALRY
4.4. OPPORTUNITY MATRIX
4.5. VENDOR LANDSCAPE
4.6. VALUE CHAIN ANALYSIS
4.7. KEY BUYING CRITERIA
5. MARKET BY TECHNOLOGY
5.1. SEQUENCING BY SYNTHESIS
5.2. ION SEMICONDUCTOR SEQUENCING
5.3. CHAIN TERMINATION SEQUENCING
5.4. PYROSEQUENCING
5.5. SEQUENCING BY LIGATION (SBL)
5.6. SINGLE-MOLECULE REAL-TIME SEQUENCING (SMRT)
5.7. NANOPORE SEQUENCING
5.8. OTHER TECHNOLOGIES
6. MARKET BY APPLICATION
6.1. BIOMARKER DISCOVERY
6.2. DIAGNOSTICS
6.3. REPRODUCTIVE HEALTH
6.4. PERSONALIZED MEDICINE
6.5. DRUG DISCOVERY
6.6. AGRICULTURE & ANIMAL RESEARCH
6.7. FORENSICS
6.8. OTHER APPLICATIONS
7. MARKET BY PRODUCT
7.1. INSTRUMENTS & CONSUMABLES
7.1.1. INSTRUMENTS & CONSUMABLES TYPE
7.1.1.1. CONSUMABLES
7.1.1.2. INSTRUMENTS
7.1.2. INSTRUMENTS & CONSUMABLES PLATFORM
7.1.2.1. NGS (NEXT GENERATION SEQUENCING)
7.1.2.1.1. RNA SEQUENCING
7.1.2.1.2. TARGETED RESEQUENCING
7.1.2.1.3. WHOLE-EXOME SEQUENCING
7.1.2.1.4. WHOLE-GENOME SEQUENCING
7.1.2.1.5. CHIP SEQUENCING
7.1.2.1.6. DE NOVO SEQUENCING
7.1.2.1.7. METHYL SEQUENCING
7.1.2.2. SANGER
7.2. SEQUENCING SERVICES
7.3. BIOINFORMATICS
8. MARKET BY END-USER
8.1. RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES
8.2. PHARMACEUTICAL
8.3. BIOTECHNOLOGY COMPANIES
8.4. HOSPITALS & CLINICS
8.5. OTHER END-USERS
9. GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1. MARKET SIZE & ESTIMATES
9.1.2. KEY GROWTH ENABLERS
9.1.3. KEY CHALLENGES
9.1.4. KEY PLAYERS
9.1.5. COUNTRY ANALYSIS
9.1.5.1. UNITED STATES
9.1.5.2. CANADA
10. COMPETITIVE LANDSCAPE
10.1. KEY STRATEGIC DEVELOPMENTS
10.1.1. MERGERS & ACQUISITIONS
10.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
10.1.3. PARTNERSHIPS & AGREEMENTS
10.1.4. BUSINESS EXPANSIONS, ANNOUNCEMENTS, AND DIVESTITURES
10.2. COMPANY PROFILES
10.2.1. ADAPTIVE BIOTECHNOLOGIES INC
10.2.2. AGILENT TECHNOLOGIES INC
10.2.3. ASURAGEN INC
10.2.4. BGI GENOMICS
10.2.5. BIO-RAD LABORATORIES INC
10.2.6. DANAHER CORPORATION (INTEGRATED DNA TECHNOLOGIES INC)
10.2.7. EUROFINS SCIENTIFIC
10.2.8. F. HOFFMANN-LA ROCHE
10.2.9. ILLUMINA INC
10.2.10. MERCK KGAA
10.2.11. PACIFIC BIOSCIENCES OF CALIFORNIA INC
10.2.12. PERKINELMER INC
10.2.13. SIEMENS HEALTHINEERS AG
10.2.14. SPIRAL GENETICS INC
10.2.15. THERMO FISHER SCIENTIFIC INC
10.2.16. UBIQUITY GENOMICS INC
1. ADAPTIVE BIOTECHNOLOGIES INC
2. AGILENT TECHNOLOGIES INC
3. ASURAGEN INC
4. BGI GENOMICS
5. BIO-RAD LABORATORIES INC
6. DANAHER CORPORATION (INTEGRATED DNA TECHNOLOGIES INC)
7. EUROFINS SCIENTIFIC
8. F. HOFFMANN-LA ROCHE
9. ILLUMINA INC
10. MERCK KGAA
11. PACIFIC BIOSCIENCES OF CALIFORNIA INC
12. PERKINELMER INC
13. SIEMENS HEALTHINEERS AG
14. SPIRAL GENETICS INC
15. THERMO FISHER SCIENTIFIC INC
16. UBIQUITY GENOMICS INC
